Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.35 Insider Own0.30% Shs Outstand47.90M Perf Week0.02%
Market Cap2.92B Forward P/E- EPS next Y-1.47 Insider Trans-49.42% Shs Float39.34M Perf Month124.11%
Income-238.70M PEG- EPS next Q-1.31 Inst Own72.70% Short Float37.61% Perf Quarter219.77%
Sales1.30M P/S2246.88 EPS this Y-53.40% Inst Trans-2.02% Short Ratio3.65 Perf Half Y205.21%
Book/sh2.63 P/B23.19 EPS next Y64.70% ROA-109.00% Target Price68.64 Perf Year89.91%
Cash/sh2.57 P/C23.71 EPS next 5Y-0.20% ROE-166.30% 52W Range8.00 - 63.73 Perf YTD58.06%
Dividend- P/FCF- EPS past 5Y0.00% ROI-103.00% 52W High-4.32% Beta1.25
Dividend %- Quick Ratio2.30 Sales past 5Y-46.80% Gross Margin- 52W Low662.25% ATR3.95
Employees270 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)76.88 Volatility5.20% 10.44%
OptionableYes Debt/Eq0.17 EPS Q/Q-33.40% Profit Margin- Rel Volume0.85 Prev Close62.24
ShortableYes LT Debt/Eq0.08 EarningsOct 18 BMO Payout- Avg Volume4.05M Price60.98
Recom1.80 SMA2053.17% SMA5095.52% SMA200168.15% Volume3,440,172 Change-2.02%
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Mar-23-16Downgrade JMP Securities Mkt Perform → Mkt Underperform
Mar-01-16Reiterated Needham Buy $55 → $53
Jan-19-16Downgrade RBC Capital Mkts Outperform → Sector Perform $62 → $15
Jan-15-16Downgrade Piper Jaffray Overweight → Neutral
Sep-29-16 12:40PM  Catabasis Skyrockets on Sarepta Partnership
11:34AM  Sarepta announces Duchenne research partnership with Cambridge's Catabasis at bizjournals.com
10:41AM  One Biotech Crashes, the Other Skyrockets -- Here's Why at Motley Fool
08:00AM  Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy Business Wire
Sep-28-16 06:00PM  Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping Business Wire +5.31%
04:21PM  Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A
03:14PM  Heres Why These Five Stocks Are Trading Higher Today at Insider Monkey
12:21PM  Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc at Motley Fool
11:15AM  Selling Into Strength Can Be a Great Strategic Move
10:26AM  RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside' at MarketWatch
10:17AM  Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys
10:04AM  Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price' at Barrons.com
08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
Sep-27-16 02:47PM  Sareptas Manufacturing Challenge (SRPT) at Investopedia
Sep-26-16 12:43PM  BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT) at Investopedia
09:56AM  Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines at Insider Monkey
Sep-25-16 10:00AM  For Traders, Planning Is More Important Than the Plan
Sep-24-16 01:24PM  2 Stocks I'd Never Buy, and 1 I'll Consider at Motley Fool
07:27AM  The Woman Behind Sarepta Therapeutics' Success at Motley Fool
01:00AM  [$$] Sarepta Still Has Upside at Barrons.com
Sep-23-16 06:50PM  Sarpeta Approval Challenged by FDA (SRPT) at Investopedia -5.15%
05:45PM  Sarpeta Raises Offering After FDA Approval (SRPT) at Investopedia
05:29PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
Sep-22-16 06:00PM  Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Business Wire +8.45%
03:22PM  3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering
01:36PM  Sarepta Announces Offering of Common Stock (SRPT) at Investopedia
12:59PM  Top trades for the 2nd half: BABA, SRPT & more
12:45PM  5 Stocks With Amazon-Like Growth Potential at Motley Fool
11:04AM  I Am One of the Underinvested Bulls Right Now
10:24AM  FDA Commish Says Sarepta's DMD Study Should Be Retracted
09:35AM  How Sarepta Is Cashing In on Its FDA Homerun at 24/7 Wall St.
08:27AM  Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and More at Insider Monkey
07:39AM  [video]Stock Futures Rise as Wall Street Finds Relief in a Patient Fed
Sep-21-16 08:58PM  Sarepta Wins Favorable USPTO Decisions (SRPT) at Investopedia
05:48PM  [$$] Sarepta to Sell Up to $225 Million of Stock at The Wall Street Journal
04:32PM  'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs
04:17PM  Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering
04:16PM  Sarepta sales slump after company announces $225 million stock offering at MarketWatch
04:00PM  Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
02:26PM  Sarepta's New Drug May Make It a Takeover (SRPT) at Investopedia
01:34PM  Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action at Barrons.com
11:58AM  Sarepta to open Andover manufacturing site soon at bizjournals.com
11:50AM  Patent Trial And Appeal Board Hands Sarepta Another Big Win
08:39AM  Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
08:31AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:23AM  At $300,000 a year, Sareptas new drug is considered a steal at MarketWatch
Sep-20-16 07:58PM  FDA Approval Leads 75% Rise in Sarepta (SRPT) at Investopedia +13.87%
05:25PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:15PM  Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical Business Wire
04:52PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
04:38PM  Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target?
04:11PM  [$$] Sarepta jumps after drugs regulator boost at Financial Times
04:07PM  Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday at Motley Fool
03:12PM  [$$] Sarepta Soars 100% in a Week Yet Remains a Buy at Barrons.com
03:01PM  Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy at Motley Fool
02:17PM  Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy? at Motley Fool
01:49PM  Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
01:49PM  Was Sarepta's Big Win a Big Mistake for the FDA? at Motley Fool
12:22PM  Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again at Motley Fool
11:46AM  Sarepta shares jump 13%, extending Monday's surge on drug approval at CNBC
11:44AM  Sarepta Therapeutics Shares Buoyed by RBC Upgrade at TheStreet
11:32AM  Why Sarepta Approval is Good News for BioMarin, Alexion at Barrons.com
11:26AM  Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval
11:24AM  FDA grants accelerated approval to Sareptas Duchenne drug at bizjournals.com
10:25AM  Company News for September 20, 2016
10:13AM  Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
09:51AM  Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA at Barrons.com
09:42AM  Stocks Open Higher; Housing Starts Miss Views
09:17AM  Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA at Forbes
08:53AM  Morning Movers: Sarepta Gains on Upgrade; Wells Fargo Rises at Barrons.com
08:45AM  Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More at 24/7 Wall St.
08:19AM  Morning Movers: CHK, WFC, SRPT
06:55AM  Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
06:00AM  Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics
02:07AM  Sarepta Soars to 150% Q3 Gains, Wal-Mart Closes Jet Deal, SeaWorld Sinks & More at Insider Monkey
12:18AM  [$$] FDA Approves Sareptas Muscular Dystrophy Drug at The Wall Street Journal
12:18AM  [$$] The Boys Who Beat the FDA at The Wall Street Journal
12:00AM  Fierce Debate at FDA on Whether Drug Decision Sets New Standard at Bloomberg
Sep-19-16 08:01PM  Why PTC Therapeutics Shares Skyrocketed 20.6% Today at Motley Fool +73.85%
07:49PM  [$$] The Boys Who Beat the FDA at The Wall Street Journal
07:08PM  Cramer Remix: Another speculative biotech with tremendous upside at CNBC
07:00PM  Cramer Remix: Another speculative biotech with tremendous...
06:56PM  How To Predict The Next Sarepta (FDA Approval Stock) And Win Big at Forbes
05:59PM  Final Trade: GM, SRPT & more
05:51PM  Sarepta's big FDA win
05:46PM  Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today at Motley Fool
05:30PM  Cause For Celebration In The Duchenne Muscular Dystrophy Community at Forbes
05:29PM  Why Sarepta Therapeutics Soared 74% Today at Motley Fool
05:15PM  [$$] FDA Approves Sarepta's Dystrophy Drug at The Wall Street Journal
05:04PM  Sarepta shares leap 90% after FDA approves drug at CNBC
04:34PM  Biotech stock explodes 73% after the FDA approves the first drug to treat a rare muscle disorder
04:10PM  Sarepta Stock Soars On FDA OK For Muscular Dystrophy Drug
04:09PM  Biotechnology ETFs Rally on Sarepta FDA Drug Approval
04:05PM  [$$] Sarepta Still a Buy After Expedited FDA Approval at Barrons.com
02:45PM  Sarepta's very good day
02:27PM  Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
01:52PM  Sarepta Therapeutics upgraded by RBC Capital Mkts
01:44PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:39PM  Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51 (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51 Business Wire
01:32PM  Short Hills Capital CIO Weiss Discusses Sarepta Therapeutic (SRPT) Stock Surge Today
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM